850197-67-0

Basic information

• Product Name: 1-chloroisoquinolin-6-ol
• Synonyms: 1-chloroisoquinolin-6-ol;1-Chloro-6-isoquinolinol
• CAS NO: 850197-67-0
• Molecular Formula: C9H6ClNO
• Molecular Weight: 179.60304
• Mol File: 850197-67-0.mol

Chemical Properties

• Boiling Point: 369.3±22.0 °C(Predicted)
• Appearance: /
• Density: 1.412±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 8.71±0.40(Predicted)
• CAS DataBase Reference: 1-chloroisoquinolin-6-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-chloroisoquinolin-6-ol(850197-67-0)
• EPA Substance Registry System: 1-chloroisoquinolin-6-ol(850197-67-0)

Safety Data

• Hazardous Substances Data: 850197-67-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Chloroisoquinolin-6-ol is utilized as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and functional groups allow it to be a key component in the creation of new drugs, potentially contributing to the development of novel therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, 1-chloroisoquinolin-6-ol serves as a building block in the production of other chemical substances. Its versatility and reactivity make it suitable for the synthesis of agrochemicals, which can be used in the development of pesticides, herbicides, and other crop protection products.
Used in Chemical Research:
1-Chloroisoquinolin-6-ol is also valuable in chemical research for its potential to be modified and functionalized to create new compounds with specific properties. Researchers can explore its reactivity and interactions with other molecules, paving the way for innovative applications in various fields.

Upstream product

• 132997-77-4 1-chloro-6-methoxyisoquinoline 

Relevant articles and documents

Hepatitis C virus inhibitors

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

6-SUBSTITUTED ISOQUINOLINE DERIVATIVES

The present invention relates to 6-substituted isoquinoline derivatives having the general Formula I wherein X is O, S or NH; Y is OH or NH2; m is 0, 1 or 2; n is 0 or 1; o is 0 or 1; R1 is H, when Y is NH2; or R1 is H, (C1-4)alkyl or halogen, when Y is OH; R2 and R3 are independently H, (C1-4)alkyl or halogen; R4 is H or (C1-6)alkyl, optionally substituted with halogen, (C3-7)cycloalkyl, (C6-10)aryl or a saturated 5- or 6-membered heterocyclic ring comprising 1-3 heteroatoms independently selected from O, S and N, the (C6-10)aryl and heterocyclic ring being optionally substituted with (C1-4)alkyl, (C1-4)alkyloxy or halogen; R5 is H or (C1-4)alkyl; or a pharmaceutically acceptable salt thereof, with the proviso that the compounds of Formula I wherein X is O, Y is OH , n is 0 and m+o=2 are excluded, to pharmaceutical compositions comprising the same, as well as to the use of said 6-substituted isoquinoline derivatives for the preparation of a medicament for the treatment of ROCK-I related disorders such as glaucoma, hypertension and atherosclerosis.

Isoquinoline derivatives

The invention relates to isoquinoline derivatives having the general Formula I wherein X is O, S or NH; Y is OH or NH2; m is 0, 1 or 2; n is 1 or 2; R1 is H, when Y is NH2; or R. is H, (C1-4)alkyl or halogen, when Y is OH; R2 and R3 are independently H, (C1-4)alkyl or halogen; R is H or (C1-6)alkyl, optionally substituted with OH, (C1-4)-alkyloxy, (C1-4)alkyloxycarbonyl, (C3-7)cycloalkyl, which may optionally comprise a heteroatom selected from O and S, (C6-10)aryl, (C6-10)aryloxy or a 5- or 6-membered heteroaryl group comprising 1-3 heteroatoms independently selected from O, N and S, each aryl or heteroaryl group being optionally substituted with 1-3 substituents independently selected from (C1-4)alkyl, (C1-4)alkyloxy, (C1-4)alkylsulfonyl and halogen; or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same as well as to the use of the isoquinoline derivatives in the treatment of ROCK-I related disorders such as hypertension, atherosclerosis and glaucoma.

ISOQUINOLINE DERIVATIVES

The invention relates to isoquinoline derivatives having the general Formula (I) wherein X is O, S or NH; Y is OH or NH2; m is 0, 1 or 2; n is 1 or 2; R1 is H, when Y is NH2; or R1 is H, (C1-4)alkyl or halogen, when Y is OH; R2 and R3 are independently H, (C1-4)alkyl or halogen; R is H or (C1-6)alkyl, optionally substituted with OH, (C1-4)- alkyloxy, (C1-4)alkyloxycarbonyl, (C3-7)cycloalkyl, which may optionally comprise a heteroatom selected from O and S, (C6-10)aryl, (C6-10)aryloxy or a 5- or 6-membered heteroaryl group comprising 1-3 heteroatoms independently selected from O, N and S, each aryl or heteroaryl group being optionally substituted with 1-3 substituents independently selected from (C1-4)alkyl, (C1-4)alkyloxy, (C1-4)alkylsulfonyl and halogen; or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same as well as to the use of the isoquinoline derivatives in the treatment of ROCK-I related disorders such as hypertension, atherosclerosis and glaucoma.